Top

Published in:

01-02-2014 | Topic paper

Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

Authors: Daniel Keizman, Maya Ish-Shalom, Natalie Maimon, Maya Gottfried

Published in: World Journal of Urology | Issue 1/2014

Abstract

One third of patients with metastatic renal cell carcinoma (RCC) suffer from bone metastases. Skeletal involvement in RCC is associated with the occurrence of skeletal-related events, and may negatively impact on the outcome of patients treated with systemic therapies. In patients with RCC and bone metastases, therapies that inhibit osteoclasts, as bisphosphonates and denosumab, are used as adjunct to systemic targeted therapies to prevent skeletal-related events. Data suggest that they may also improve the outcome of systemic targeted therapies. Herein we review the preclinical and clinical data on their use, as well as remaining open questions.

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38:284–291PubMedCrossRef

Lam JS, Leppert JT, Belldegrun AS, Figlin RA (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23:202–212PubMedCrossRef

Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875PubMedCrossRef

Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30:843–852PubMedCrossRef

Zagoria RJ, Bechtold RE (1997) The role of imaging in staging renal adenocarcinoma. Semin Ultrasound CT MR 18:91–99PubMedCrossRef

Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160–166PubMedCrossRef

Zekri J, Ahmed N, Coleman RE, Hancock BW (2011) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19:379–382

Khattak MA, Martin HL (2012) Management of bone metastases from advanced renal cell carcinoma. Eur J Cancer Jun 6. [Epub ahead of print]

10.

Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22:794–800PubMedCrossRef

11.

Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22:295–300PubMedCrossRef

12.

Yuasa T, Urakami S, Yamamoto S et al (2011) Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis 28:405–411PubMedCrossRef

13.

Tan TH, Pranavan G, Haxhimolla HZ, Yip D (2010) New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia Pacific J Clin Oncol 6:5–18CrossRef

14.

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. NEJM 356:115–124PubMedCrossRef

15.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCrossRef

16.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

17.

Maita S, Yuasa T, Tsuchiya N, Mitobe Y, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T, Habuchi T (2012) Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer 130:677–684PubMedCrossRef

18.

Karaca H, Lale A, Dikilitas M, Ozkan M, Er O (2010) Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Med Oncol 27:1023–1026PubMedCrossRef

19.

Żolnierek J, Nurzyński P, Langiewicz P et al (2009) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136:371–378PubMedCrossRef

20.

Saad F, Eastham JA (2010) Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 37(Suppl 1):S38–S44. Review

21.

Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157PubMedCrossRef

22.

Rosen LS, Gordon D, Tchekmedyain NS et al (2004) Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumours. Cancer 100:2613–2621PubMedCrossRef

23.

Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962–969PubMedCrossRef

24.

Ullen A, Schwarz S, Lennartsson L et al (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 43:98–103PubMedCrossRef

25.

Pandha H, Birchall L, Meyer B et al (2006) Antitumor effects of amino bisphosphonates on renal cell carcinoma cell lines. J Urol 176:2255–2261PubMedCrossRef

26.

Soltau J, Zirrgiebel U, Esser N et al (2008) Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 28:933–941PubMed

27.

Kijima T, Fujii Y, Suyama T, Okubo Y, Yonese J, Fukui I (2008) Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. Int J Urol 15:546–547PubMedCrossRef

28.

Beuselinck BL, Medioni J, Wolter P et al (2011) Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib. J Clin Oncol 29(suppl 7), abstr 388

29.

Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer 48:1031–1037PubMedCrossRef

30.

Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I (2012) Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol Sep 11. [Epub ahead of print]

31.

Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664PubMedCrossRef

32.

Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y (2009) Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218:530–539PubMedCrossRef

33.

Henry DH, Costa L, Goldwasser FJ et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132PubMedCrossRef

34.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468PubMedCrossRef

35.

Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9–17PubMedCrossRef

36.

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347PubMedCrossRef

37.

Christodoulou C, Pervena A, Klouvas G et al (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211PubMedCrossRef

38.

Ayllon J, Vacher-Launay V, Medioni J, Cros C, Spano JP, Oudard S (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20:600–601PubMedCrossRef

39.

Brunello A, Saia G, Bedogni A, Scaglioni D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44:173–175PubMedCrossRef

40.

Hoefert S, Eufinger H (2010) Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110:463–469PubMedCrossRef

41.

Aragon-Ching JB, Dahut WL (2008) Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association? Oncologist 13:1314PubMedCrossRef

42.

Chennuru S, Koduri J, Baumann MA (2008) Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J 38:635–637PubMedCrossRef

43.

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822PubMedCentralPubMedCrossRef

Title: Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?
Authors: Daniel Keizman
Maya Ish-Shalom
Natalie Maimon
Maya Gottfried
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 1/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1059-6

At a glance: The STEP trials

Springer Medicine

Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy

Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORd Project)

The role of functional imaging in the era of targeted therapy of renal cell carcinoma

Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group

Imaging the urologic patient: the utility of intravenous pyelogram in the CT scan era

Robotic-assisted laparoendoscopic single-site radical nephrectomy: first experience with the novel Da Vinci single-site platform